Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.833
Peer-review started: October 11, 2023
First decision: December 5, 2023
Revised: December 19, 2023
Accepted: January 24, 2024
Article in press: January 24, 2024
Published online: March 15, 2024
Processing time: 153 Days and 2.1 Hours
Some studies have shown that the number of dissected lymph nodes (LNs) was significantly lower in patients with gastric remnant cancer (GRC). Since traditional LN stage (N stage) seems inaccurate for the evaluation, other studies have suggested an alternative to N stage, which is dependent on the absolute number of metastatic LNs required for GRC.
To explore a superior predictor in surgically treated locally advanced GRC.
To evaluate the impact of LN ratio (LNR) on clinicopathological characteristics and prognosis in patients with GRC.
The relationship between LNR and clinicopathological characteristics was analyzed. The survival analysis was performed using Kaplan-Meier survival curves and Cox regression model.
The 1-, 3- and 5-year overall survival rates were 81.9%, 44.5% and 27.4%, and the median survival time was 31.0 mo. The median survival time for those with LNR0, LNR1, LNR2 and LNR3 stage was 61, 31, 23 and 17 mo, respectively, and the difference was significant. Univariate analysis revealed that the factors affecting survival included tumor diameter, anemia, serum tumor biomarkers, vascular or neural invasion, combined resection, N stage, LNR stage and TNM stage. Anemia, level of serum tumor biomarkers and LNR stage were independent prognostic factors for survival in multivariable analysis.
Compared with N stage, the new LNR stage is uniquely based on the number of metastatic LNs. LNR stage has significant prognostic value for patients with locally advanced GRC, and it could better differentiate overall survival in patients than N stage.
In the future, we will work with other hospitals to increase the number of samples and evaluate whether LNR is better at predicting the need for adjuvant treatment than N stage.